JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD

Reference Data

ISIN LU2050612402
Valor Number
Bloomberg Global ID
Fund Name JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD
Fund Provider J.P. Morgan Bank Luxembourg S.A. 6, route de Trèves
L-2633, Senningerberg
Grand Duchy of Luxembourg
Fund Provider J.P. Morgan Bank Luxembourg S.A.
Representative in Switzerland JPMorgan Asset Management (Switzerland) LLC
Genève
Phone: +41 22 744 11 11
Distributor(s) JP Morgan Asset Management (Europe) Sàrl
Senningerberg
Phone: +352 34 10 1
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally.
Peculiarities

Fund Prices

Current Price * 77.82 USD 14.04.2025
Previous Price * 75.12 USD 11.04.2025
52 Week High * 108.58 USD 26.07.2024
52 Week Low * 72.17 USD 09.04.2025
NAV * 77.82 USD 14.04.2025
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 367,024,352
Unit/Share Assets *** 105,063,796
Trading Information SIX

Performance

YTD Performance -13.70% 31.12.2024
14.04.2025
YTD Performance (in CHF) -21.98% 31.12.2024
14.04.2025
1 month -14.16% 14.03.2025
14.04.2025
3 months -11.92% 14.01.2025
14.04.2025
6 months -22.30% 14.10.2024
14.04.2025
1 year -20.94% 15.04.2024
14.04.2025
2 years -26.26% 14.04.2023
14.04.2025
3 years -36.02% 14.04.2022
14.04.2025
5 years -30.97% 14.04.2020
14.04.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Bristol-Myers Squibb Co 3.60%
Gilead Sciences Inc 3.55%
Amgen Inc 3.53%
Novartis AG Registered Shares 3.52%
Alnylam Pharmaceuticals Inc 3.40%
Vertex Pharmaceuticals Inc 3.33%
Krystal Biotech Inc 3.32%
Lonza Group Ltd 3.32%
Takeda Pharmaceutical Co Ltd 3.20%
PTC Therapeutics Inc 3.14%
Last data update 31.03.2025

Cost / Risk

TER *** 0.94%
TER date *** 31.12.2024
Performance Fee ***
PTR
Max. Management Fee *** 0.72%
Ongoing Charges *** 0.95%
SRRI ***
SRRI date *** 31.03.2025

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)